Rethinking end-points for bone-targeted therapy in advanced cancer

Area of Science:

• Oncology
• Clinical Trials
• Medical Therapy

Background:

• Bone metastases can cause skeletal-related events (SREs), measuring skeletal morbidity.
• SREs are a primary endpoint in bone-targeted therapy trials for patients with skeletal metastases.
• Current bone-targeted therapies have not improved progression-free survival, overall survival, or consistently improved quality of life.

Purpose of the Study:

• To evaluate the efficacy of bone-targeted therapy in patients with skeletal metastases.
• To question the validity of SREs as primary outcome measures in cancer clinical trials.
• To explore novel endpoint selections for bone-targeted therapy trials.

Main Methods:

• Analysis of clinical trials evaluating bone-targeted therapy in patients with skeletal metastases.
• Comparison of SRE occurrence rates between bone-targeted therapy and placebo/other agents.
• Assessment of effects on progression-free survival, overall survival, and quality of life.

Main Results:

• Bone-targeted therapies have reduced SRE frequency but failed to improve progression-free or overall survival.
• Consistent improvements in quality of life have not been demonstrated with bone-targeted therapies.
• The validity of SREs as primary outcome measures in cancer trials is questionable.

Conclusions:

• SREs alone may not be sufficient primary outcome measures for bone-targeted therapy trials.
• Novel endpoints, such as composite measures of symptomatic skeletal events and patient-reported outcomes, are warranted.
• Further investigation into composite endpoints could provide a more effective evaluation of bone-targeted therapies.